Ramucirumab
15679
Phase 3 small_molecule completed
Quick answer
Ramucirumab for Urothelial Carcinoma is a Phase 3 program (small_molecule) at Eli Lilly and Company with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Eli Lilly and Company
- Indication
- Urothelial Carcinoma
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed